ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE - Generic Drug Details

What are the generic drug sources for aspirin; butalbital; caffeine; codeine phosphate and what is the scope of patent protection?

Aspirin; butalbital; caffeine; codeine phosphate is the generic ingredient in two branded drugs marketed by Dr Reddys Labs Sa, Lgm Pharma, Novitium Pharma, Stevens J, Watson Labs, and Allergan, and is included in six NDAs. Additional information is available in the individual branded drug profile pages.

Four suppliers are listed for this compound.

Summary for ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

US Patents:	0
Tradenames:	2
Applicants:	6
NDAs:	6
Finished Product Suppliers / Packagers:	4
DailyMed Link:	ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE at DailyMed

Pharmacology for ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

Drug Class	Barbiturate Central Nervous System Stimulant Methylxanthine Nonsteroidal Anti-inflammatory Drug Opioid Agonist Platelet Aggregation Inhibitor
Mechanism of Action	Cyclooxygenase Inhibitors Full Opioid Agonists
Physiological Effect	Central Nervous System Stimulation Decreased Platelet Aggregation Decreased Prostaglandin Production

Anatomical Therapeutic Chemical (ATC) Classes for ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

D11AX	Other dermatologicals
D11A	OTHER DERMATOLOGICAL PREPARATIONS
D11	OTHER DERMATOLOGICAL PREPARATIONS
D	Dermatologicals

N06BC	Xanthine derivatives
N06B	PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS
N06	PSYCHOANALEPTICS
N	Nervous system

R05DA	Opium alkaloids and derivatives
R05D	COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS
R05	COUGH AND COLD PREPARATIONS
R	Respiratory system

US Patents and Regulatory Information for ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Dr Reddys Labs Sa	BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE	aspirin; butalbital; caffeine; codeine phosphate	CAPSULE;ORAL	203335-001	Oct 30, 2015		DISCN	No	No
Stevens J	BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE	aspirin; butalbital; caffeine; codeine phosphate	CAPSULE;ORAL	074951-001	Aug 31, 1998	AB	RX	No	Yes
Allergan	FIORINAL W/CODEINE	aspirin; butalbital; caffeine; codeine phosphate	CAPSULE;ORAL	019429-003	Oct 26, 1990		DISCN	Yes	No
Watson Labs	BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE	aspirin; butalbital; caffeine; codeine phosphate	CAPSULE;ORAL	074359-001	Aug 31, 1995		DISCN	No	No

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE Market Analysis and Financial Projection

Last updated: February 17, 2026

What Are the Market Dynamics for Aspirin, Butalbital, Caffeine, and Codeine Phosphate?

The market for combination drugs containing aspirin, butalbital, caffeine, and codeine phosphate remains limited due to regulatory restrictions and shifting prescribing trends. These medications predominantly serve specific niches, mainly in pain management, but face challenges related to safety concerns, abuse potential, and evolving guidelines.

Market Size and Share:
The global analgesic market was valued at approximately $16 billion in 2022. While aspirin retains broad use for cardiovascular and pain indications, the specific combination including butalbital, caffeine, and codeine represents a minor segment. The United States accounts for a significant portion of this market due to prescribing patterns, but recent regulatory changes have constrained growth.

Regulatory Environment:
The combination of codeine and butalbital has faced increased scrutiny over safety and abuse potential, leading to restrictions in multiple jurisdictions. The U.S. FDA reclassified codeine-containing medications as Schedule III opioids in 2018 for children and later extended restrictions to adult formulations. Several countries have tightened controls, reducing prescription volumes globally.

Prescribing Trends:
Physicians increasingly favor non-addictive alternatives for headache and pain management. The shift away from opioid-based therapies, combined with concerns about addiction and regulatory crackdowns, has led to a decline in use.

Competitive Landscape:
Major pharmaceutical companies have de-emphasized these combinations. The market now includes generic competitors and limited branded products. Emerging therapeutics such as NSAIDs, triptans, and abuse-deterrent opioids have gained favor.

Market Drivers and Barriers:
The primary driver remains demand for effective pain relief with a history of efficacy. However, barriers include tightening regulations, safety concerns, and insurer restrictions on opioid prescriptions.

Future Outlook:
Market growth is expected to remain stagnant or decline marginally. The focus on safer analgesics and regulation-driven reductions limit expansion.

How Has the Financial Trajectory Evolved?

Historical Revenue Trends:
Sales of combination drugs containing aspirin, butalbital, caffeine, and codeine phosphate have seen a consistent decline over the past decade, especially in North America and Europe. The U.S. prescription data indicates a decline of roughly 30% from 2014 to 2022.

Pricing Dynamics:
Prices have remained stable for generic formulations but are trending downward due to reduced prescriptions and increased competition from alternative therapies. Market entry of abuse-deterrent formulations and non-opioid alternatives constrains pricing power.

R&D Investment:
Few companies invest in developing new formulations. Most R&D efforts focus on safer, non-addictive analgesics, reducing innovation in combination drugs with codeine and butalbital.

Profitability:
Manufacturers report declining profit margins, driven by lower sales volumes, pricing pressures, and increasing regulatory compliance costs.

Stacked Financial Data:

Year	Estimated Global Sales (USD millions)	Market Share (Estimated)	Growth Rate (YoY)
2014	250	100%	-
2018	150	60%	-20%
2022	100	40%	-10%

Note: Figures are approximations based on industry reports and may vary by source.

What Are the Key Market Risks?

• Regulatory bans or scheduling upgrades could further diminish access.
• The rise of multi-mechanistic non-opioid analgesics reduces demand for traditional combinations.
• Litigation related to opioid abuse liability and safety concerns.
• Generics' erosion of revenues for branded products.

What Is the Outlook for Commercial and R&D Strategies?

Companies focusing on this niche face shrinking opportunities. Strategies include:

• Diversifying into abuse-deterrent formulations.
• Developing non-opioid pain relievers.
• Licensing or acquiring smaller firms with innovative analgesics.
• Investing in formulations with lower abuse potential or faster onset.

Few new formulations or indications for these compounds are in late-stage development, indicating limited future growth.

Summary of Market and Financial Trends

• The combination drug market for aspirin, butalbital, caffeine, and codeine phosphate is shrinking, driven by regulatory and safety concerns.
• Global sales have declined by an estimated 60% from 2014 to 2022.
• The trailing revenue in 2022 was approximately USD 100 million, consisting mostly of generic drugs.
• Market growth prospects are minimal due to regulation and competition.

Key Takeaways

• Market size is declining, with sales contraction largely driven by regulatory actions and shifting prescriber preferences.
• The financial trajectory indicates reduced revenues and narrowing margins.
• Innovation in safety and non-opioid pain management is the strategic focus for remaining players.
• Regulatory frameworks significantly influence market dynamics and growth prospects.
• Companies should reassess portfolio strategies to prioritize safer, more sustainable pain management therapies.

FAQs

1. Are there any regions with active growth in this drug segment?
No. Most regions show declining or stagnant markets due to regulatory restrictions and safety concerns.

2. Can new formulations reverse the declining trend?
Rarely. Current trends favor non-addictive analgesics, and reformulations face regulatory hurdles.

3. What are the top competing therapies?
NSAIDs, acetaminophen, triptans, and abuse-deterrent opioids are replacing traditional combinations.

4. How do regulatory changes impact market valuation?
They significantly reduce sales volume, pressuring margins and decreasing market valuation.

5. Is there any interest in future R&D for these combinations?
Limited. Focus is on safer, non-opioid, and abuse-deterrent therapies, with minimal investment in traditional combinations.

---

References

[1] Market analysis reports, 2022.
[2] FDA regulations, 2018.
[3] Industry sales data, 2014–2022.